Bilateral hearing loss during vincristine therapy: a case report.
Vincristine sulfate is a chemotherapeutic agent used in different cancer therapies. It is also the first choice of treatment for peripheral T-cell lymphoma with cyclophosphamide and adriamycin. Sudden hearing loss during vincristine therapy is a very rare event. This is a case of a 16-year old girl who developed sudden bilateral hearing loss related to vincristine therapy.
Kalcioglu
M T
MT
Department of Otolaryngology, Inonu University Faculty of Medicine, Malatya, Turkey. mtkalcioglu@hotmail.com
Kuku
I
I
Kaya
E
E
Oncel
S
S
Aydogdu
I
I
D000293:Adolescent; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D001299:Audiometry; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017809:Fatal Outcome; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine